RxDoctor Payments Data

Jonathan Adler, MD

Ophthalmology · Bradenton, FLNPI 1063541076

Payments from drug & device makers

$3,071in general payments, 2019–2025

Across 59 payments — averaging $52.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$990
  • Bausch & Lomb Americas Inc.$475
  • AbbVie$360
  • Biotissue Holdings Inc.$197
  • Amgen$186
  • Sun Pharmaceutical Industries Inc.$156
  • plus $708 from 9 others

What the payments were for

  • Food & beverage$3,03099%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,071 in reported general payments places this provider in the 55th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$241,980
Medicare patients
757
Services billed
1,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine44$50,814
LumiganBimatoprost31$22,479
XiidraLifitegrast18$22,014
Cyclosporine13$7,823
TobradexTobramycin/Dexamethasone29$7,697
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol28$7,673
Prednisolone Acetate174$6,363
Tobradex StTobramycin/Dexamethasone11$2,551
Latanoprost278$2,415
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha242$2,374
Doxycycline Hyclate87$1,679
Brimonidine Tartrate135$1,241
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat40$873
Timolol Maleate75$834
Acyclovir21$724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$360$73,29275 claims
Bausch & Lomb Americas Inc.Xiidra$475$22,01418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →